> Research Use Only Disclaimer: Sermorelin (as a bulk research peptide) has not been approved by the FDA for use in healthy adults or for anti-aging purposes. The FDA approved Geref® (sermorelin acetate) in 1997 for treatment of idiopathic growth hormone deficiency in children; that product was voluntarily withdrawn by the manufacturer in 2008. This article summarizes publicly available scientific literature for educational and research purposes only. Not for human use.
---
What Is Sermorelin?
Sermorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) comprising the first 29 amino acids of the endogenous 44-residue GHRH peptide — hence its scientific designation GHRH(1-29)-NH₂. This 29-amino-acid fragment retains complete biological activity at the pituitary GHRH receptor while being substantially shorter (and thus more economical to synthesize) than native GHRH(1-44).
The compound occupies a historically important position in peptide endocrinology. GHRH itself was isolated nearly simultaneously in 1982–1983 by two competing groups — Roger Guillemin's laboratory at the Salk Institute and Wylie Vale's group, and independently by Andrew Schally — from human pancreatic tumors causing acromegaly. This discovery ultimately contributed to Roger Guillemin and Andrew Schally sharing the 1977 Nobel Prize in Physiology or Medicine for earlier work on hypothalamic hormones. The structural characterization of GHRH enabled researchers to design truncated analogs, of which sermorelin (the 1-29 fragment) proved to possess the full receptor-activating capacity of the full-length molecule.
Regulatory history of sermorelin:
- •1990: FDA approved sermorelin injection (0.05 mg/amp, brand name Geref) as a diagnostic agent for growth hormone deficiency
- •1997: FDA approved Geref at 0.5 mg/vial for treatment of idiopathic GHD-related growth failure in children
- •2008: EMD Serono voluntarily withdrew Geref from the US market as recombinant human GH (rhGH) displaced it commercially; pediatric GHD is now primarily managed with rhGH
- •Post-2008: Sermorelin remains available through compounding pharmacies and research chemical suppliers as a bulk peptide
Because of this history, sermorelin occupies a unique position among research peptides: it is the only growth hormone-releasing peptide with a completed FDA approval pathway for a closely related indication, lending its safety and pharmacology data exceptional depth compared to most research peptides.
---
Mechanism of Action: GHRHR Agonism and Pulsatile GH Release
Sermorelin's primary mechanism is agonism at the growth hormone-releasing hormone receptor (GHRHR), a class B (secretin-family) G protein-coupled receptor expressed predominantly on pituitary somatotroph cells.
Receptor Binding and Signal Transduction
When sermorelin binds GHRHR, it activates the Gαs–adenylyl cyclase–cAMP–PKA intracellular signaling cascade:
1. Gαs activation stimulates adenylyl cyclase, raising intracellular cAMP
2. PKA phosphorylation of downstream transcription factors (including CREB) upregulates GH gene expression
3. Calcium influx via voltage-gated channels facilitates fusion of GH-containing secretory granules with the cell membrane
4. GH exocytosis releases GH pulses into portal circulation
The downstream consequence is elevation of circulating growth hormone, which in turn stimulates hepatic and peripheral IGF-1 synthesis — the primary mediator of GH's anabolic and tissue-maintenance effects.
Preservation of Hypothalamic Feedback — The Key Advantage Over rhGH
Unlike exogenous recombinant human growth hormone (rhGH), sermorelin operates through the body's existing regulatory architecture:
- •Somatostatin modulation: The hypothalamus releases somatostatin (SRIH) in alternating waves with GHRH. Sermorelin stimulates GH release only during somatostatin troughs, preserving the natural pulsatile pattern. This is in direct contrast to rhGH injections, which produce pharmacologically supraphysiological, non-pulsatile GH elevations.
- •Hypothalamic feedback loop: Elevated GH and IGF-1 suppress further GHRHR signaling via negative feedback. This ceiling effect limits GH overproduction and maintains physiological range.
- •Receptor-level negative feedback: Chronic somatotroph stimulation induces receptor downregulation, providing additional auto-regulation.
This feedback preservation is why sermorelin is considered to have a favorable physiological safety profile compared to rhGH — it cannot produce the supraphysiological GH levels associated with acromegalic complications.
Pharmacokinetics
- •Half-life (subcutaneous): ~12–15 minutes due to DPP-IV cleavage at the Ala²–Asp³ bond and non-specific peptidase activity
- •Bioavailability: ~7% subcutaneous vs. intravenous due to hepatic first-pass peptidolysis
- •Peak GH response: 30–60 minutes after subcutaneous administration
- •Duration of GH elevation: Typically 2–4 hours post-injection
- •Inactivation: Primarily by plasma DPP-IV (cleaves N-terminal Tyr¹–Ala²)
The short half-life is one reason sermorelin has largely been superseded by CJC-1295 in research settings — CJC-1295's substitutions at positions 2, 8, 15, and 27 dramatically extend its plasma stability. However, the short half-life also means sermorelin more faithfully mimics the natural transient GHRH pulses from the hypothalamus.
---
Comparison: Sermorelin vs CJC-1295 vs Tesamorelin
| Parameter | Sermorelin | CJC-1295 (No DAC) | CJC-1295 (with DAC) | Tesamorelin |
|---|---|---|---|---|
| Length | 29 AA | 29 AA (modified) | 29 AA + DAC | 44 AA |
| Half-life | ~12-15 min | ~30 min | ~6-8 days | ~26 min |
| GH pattern | Pulsatile | Pulsatile | Sustained | Pulsatile |
| FDA approved | Yes (historical, withdrawn) | No | No | Yes (HIV lipodystrophy) |
| DPP-IV resistance | Low | High | High | High |
| Research cost | Low | Low-moderate | Moderate | Higher |
| Key advantage | Historical safety data; feedback preserved | Extended half-life | Once/twice weekly dosing | FDA-approved indication |
For a detailed comparison, see our CJC-1295 vs Sermorelin comparison guide and the GHRH Analogs Compared overview.
---
Key Research Studies
Pediatric GHD Clinical Trials (FDA Pivotal Studies)
The FDA pivotal studies supporting Geref's 1997 approval demonstrated that daily subcutaneous sermorelin increased growth velocity in approximately 74% of children with idiopathic GHD after 6 months of treatment. Height velocity improvements were sustained over 12 months of continuous administration.
Vittone et al. 1997 — Sermorelin in Aging Men
This 6-week study administered 2 mg of subcutaneous sermorelin nightly to 11 healthy men aged 64–76 years. The primary finding was a near-doubling of nocturnal GH output, measured by frequent GH sampling. IGF-1 levels, however, did not significantly increase over this short timeframe, highlighting that the GH/IGF-1 axis response in older adults may require longer treatment periods to fully manifest.
Sermorelin as a Diagnostic Tool (PMID 18031173)
A comprehensive review confirmed that intravenous sermorelin at 1 μg/kg body weight constitutes a rapid and relatively specific provocative test for GH deficiency diagnosis. The review noted that the combination of sermorelin plus arginine provides greater diagnostic specificity than sermorelin alone, particularly in adults — a paradigm now extended to the use of GHRH+arginine as a gold-standard stimulation test for adult GHD diagnosis.
GH Secretagogue Safety and Efficacy Review (PMID 28830317)
Studies in hypogonadal men demonstrated that GH secretagogue treatment significantly raised serum IGF-1 levels compared to placebo, supporting the physiological activity of GHRH-class peptides as GH axis amplifiers in populations with suboptimal baseline GH secretion.
Sleep-Stage GH Secretion Research
Sermorelin has been used as a research tool to study the tight coupling between GH pulsatility and slow-wave sleep (SWS). Endogenous GHRH is the primary driver of sleep-onset GH pulses; sermorelin administration in sleep studies consistently amplifies the nocturnal GH pulse concordant with SWS onset, making it valuable for circadian GH biology research.
---
Research Applications
Sermorelin is used in research models to study:
- •GH deficiency models — positive control for somatotroph function
- •Aging and GH axis decline — studying somatopause physiology
- •Pulsatility-dependent GH signaling — comparing pulsatile vs. sustained GH in downstream tissue effects
- •Body composition research — lean mass and fat mass changes under GHRH stimulation
- •Sleep and GH coupling — the GHRH–SWS neuroendocrine axis
- •Comparative pharmacology — baseline comparator when testing newer GHRH analogs (CJC-1295, tesamorelin)
---
Sourcing & Price Comparison (2026 Live Data)
The following pricing data was extracted from the Peptides.SO database of active supplier listings. All prices are per milligram (mg) of peptide.
| Supplier | Price/mg | Notes |
|---|---|---|
| Hydro Research | $0.06/mg | 10 mg vials |
| Apex Peptides | $0.10/mg | 10 mg vials |
| NG Peptide | $4.50/mg | — |
| Pepvida Labs | $6.08/mg | 13 mg vials |
| Peptides World | $6.90/mg | — |
| Empower Peptides | $6.90/mg | — |
Typical research quantities: Sermorelin is commonly supplied in 2 mg, 5 mg, or 10 mg lyophilized vials. Research protocols typically use 0.2–2 mg per administration, meaning a 10 mg vial supports 5–50 research administrations depending on dose.
> Prices fluctuate. Use the Peptides.SO sermorelin comparison tool for real-time pricing across all listed suppliers. See also: sermorelin dosage guide and ipamorelin vs sermorelin comparison.
---
Frequently Asked Questions
Q: Is sermorelin the same as GHRH?
A: Sermorelin is the first 29 amino acids of endogenous human GHRH (which is 44 amino acids). The 1-29 fragment retains full biological activity at the GHRH receptor, making sermorelin functionally equivalent to GHRH for most research purposes. It is shorter, cheaper to synthesize, and was the basis for the FDA-approved drug Geref.
Q: How does sermorelin differ from CJC-1295?
A: Both are based on GHRH(1-29), but CJC-1295 incorporates four amino acid substitutions (positions 2, 8, 15, 27) that dramatically increase DPP-IV resistance and plasma half-life. Sermorelin's shorter half-life (~12-15 min) means more frequent dosing in research protocols, but may more faithfully recapitulate natural hypothalamic GHRH pulsatility. The DAC-modified CJC-1295 extends half-life to ~6-8 days via albumin binding, creating sustained rather than pulsatile GH release.
Q: Why did Geref (branded sermorelin) get withdrawn?
A: EMD Serono voluntarily withdrew Geref in 2008 due to commercial reasons — recombinant human GH (rhGH) had become the dominant treatment for pediatric GHD, making the market for sermorelin too small to justify continued manufacturing. There were no safety concerns driving the withdrawal.
Q: What is the significance of "pulsatile" GH release in research?
A: GH is naturally secreted in pulses (primarily overnight), and many of GH's downstream effects — including IGF-1 production and anabolic signaling — are optimized by pulsatile rather than constant exposure. Research has suggested that trough periods between pulses are important for maintaining receptor sensitivity and for the specific pattern of IGF-1 gene expression. Sermorelin preserves this pulsatility, unlike continuous-infusion GH paradigms.
Q: Can sermorelin be stacked with GHRPs in research?
A: In preclinical and clinical research, GHRH analogs and GHRPs (such as GHRP-2, GHRP-6, or ipamorelin) are frequently combined because they act through synergistic but distinct pathways — GHRH via the Gαs/cAMP/PKA pathway and GHRPs via GHS-R1a/Gαq/PKC. The combination consistently produces greater GH release than either compound alone. See: body composition GH peptide research stack and best GH peptides guide.
Q: What safety signals were identified in the FDA clinical program?
A: The Geref clinical program identified injection-site redness and swelling as the most common adverse effects. Rare cases of antibody formation against sermorelin were reported, though these did not appear to affect efficacy. Flushing and headache were occasionally reported. No serious cardiovascular, metabolic, or neoplastic signals emerged in the pediatric or diagnostic adult studies.
Q: Is there published data on sermorelin in adults for anti-aging?
A: Small investigational studies (like the Vittone 1997 study in 64-76-year-old men) explored sermorelin's effects on GH secretion in aging. Results showed reliable GH pulse amplification but modest IGF-1 changes over short durations. Long-term controlled data in healthy adults for body composition or anti-aging outcomes are limited; this remains an active research question.
---
Disclaimer
This article is for educational and research informational purposes only. Sermorelin as a bulk research chemical has not been approved by the FDA for use in healthy adults. All information presented reflects published scientific literature and does not constitute medical advice, treatment recommendation, or endorsement of any specific vendor or product. Researchers should comply with all applicable regulations in their jurisdiction. For Research Use Only — Not for Human Consumption.
---
Related articles: Sermorelin dosage research guide · CJC-1295 Research Profile 2026 · Ipamorelin Research Profile 2026 · GHRH Analogs Compared